Screener
ADMA Biologics ADMA Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
FAQ
- What is ADMA Biologics's total liabilities?
- ADMA Biologics (ADMA) reported total liabilities of $276M in Q2 2026.
- How has ADMA Biologics's total liabilities changed year-over-year?
- ADMA Biologics's total liabilities increased by 72.4% year-over-year, from $160.06M to $276M.
- What is the long-term trend for ADMA Biologics's total liabilities?
- Over 5 years (2020 to 2025), ADMA Biologics's total liabilities has grown at a 4.2% compound annual growth rate (CAGR), from $119.42M to $146.92M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about ADMA Biologics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude